Late effects on the urinary bladder in patients treated for cancer in childhood: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 52, Issue 4, 2009, Pages 439-446

  Ritchey, Michael ^a,f   Ferrer, Fernando ^b   Shearer, Patricia ^c   Spunt, Sheri L ^d,e  

^a MAYO CLINIC   (United States)

^b Hartford Regional Lead Treatment Center   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f NONE   (United States)

Author keywords

Child; Late effect; Neoplasm; Urinary bladder; Urinary tract

Indexed keywords

ACETYLCYSTEINE; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MESNA; ANTINEOPLASTIC AGENT;

BLADDER CARCINOMA; BLADDER DISEASE; BLADDER DYSFUNCTION; BLADDER FIBROSIS; BLADDER FUNCTION; BLADDER INJURY; BLADDER IRRIGATION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CHILDHOOD CANCER; CYSTECTOMY; DRUG BINDING; DRUG MEGADOSE; EWING SARCOMA; HEMORRHAGIC CYSTITIS; HUMAN; LEIOMYOSARCOMA; MEDICAL LITERATURE; NEUROGENIC BLADDER; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; REVIEW; BLADDER; CHILD; DRUG EFFECT; NEOPLASM; RADIATION EXPOSURE; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; CHILD; GUIDELINES AS TOPIC; HUMANS; NEOPLASMS; RADIOTHERAPY; URINARY BLADDER; URINARY BLADDER DISEASES;

EID: 62449222138     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21826     Document Type: Review

References (59)

1. Jemal A, Siegel R, Ward E. et al. CA Cancer J Clin 2008;58:71-96.
2. Landier W, Bhatia S, Eshelman DA, et al. Development of risk- based guidelines for pediatric cancer survivors: The children's oncology group long-term follow-up guidelines from the children's oncology group late effects committee and nursing discipline. J Clin Oncol 2004;22:4979-4990.
3. McGuire EJ, Woodside JR, Borden TA, et al. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981;126: 205-209.
4. Sklar CA, LaQuaglia MP. The long-term complications of chemotherapy in childhood genitourinary tumors. Urol Clin N Am 2000;27:563-568.
5. Heyn R, Raney RB, Jr., Hays DM, et al. Late effects of therapy in patients with paratesticular rhabdomyosarcoma. Intergroup rhab- domyosarcoma study committee. J Clin Oncol 1992;10:614-623.
6. Stillwell TJ, Benson RC Jr, Burgert EO Jr. Cyclophosphamide- induced hemorrhagic cystitis in Ewing's sarcoma. J Clin Oncol 1988;6:76-82.
7. Hale GA, Marina NM, Jones-Wallace D, et al. Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 1999;21:115-122.
8. Brock N. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxaza- phosphorine cytostatics. Recent Results Cancer Res 1980;74:270-278.
9. Brock N, Pohl J, Stekar J. Detoxification of urotoxic oxazaphos- phorines by sulfhydryl compounds. J Cancer Res Clin Oncol 1981; 100:311-320.
10. Sarosy G. Ifosfamide-Pharmacologic overview. Semin Oncol 1989;16:2-8.
11. Levine LA, Richie JP. Urological complications of cyclophosphamide. J Urol 1989;141:1063-1069.
12. Williams J, Clarke D. Pelvic radiation necrosis and radiation cystitis. In: Kindwall E, editor. Hyperbaric medicine practice. Arizona: Best Publishing; 1994: p 505.
13. Tefft M, Lattin PB, Jereb B, et al. Acute and late effects on normal tissues following combined chemo-and radiotherapy for childhood rhabdomyosarcoma and Ewing's sarcoma. Cancer 1976;37:1201-1217.
14. Gorcynska E, Turkiewicz D, Rybka K, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005;11:797-804.
15. Luce JK, Simons JA. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. Med Pediatr Oncol 1988;16:372-374.
16. Jerkins GR, Noe HN, Hill D. Treatment of complications of cyclophosphamide cystitis. J Urol 1988;139:923-925.
17. Dorr W, Beck-Bornholdt HP. Radiation-induced impairment of urinary bladder function in mice: Fine structure of the acute response and consequences on late effects. Radiat Res 1999;151: 461 -467.
18. Kallfass E, Kramling HJ, Schultz-Hector S. Early inflammatory reaction of the rabbit coeliac artery wall after combined intra- operative (IORT) and external (ERT) irradiation. Radiother Oncol 1996;39:167-178.
19. KraftM, Oussoren Y, StewartFA, etal. Radiation-induced changes in transforming growth factor beta and collagen expression in the murine bladder wall and its correlation with bladder function. Radiat Res 1996;146:619-627.
20. Lundbeck F, Oussoren Y, Stewart FA. Early and late damage in the mouse bladder after radiation combined with cyclophosphamide or cisplatinum, evaluated by two different functional assays. Acta Oncol 1993;32:679-687.
21. Woloschak GE, Chang-Liu CM, Jones PS, et al. Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res 1990;50:339-344.
22. Yue TL, Wang XK, Olson B, et al. Interleukin-1 beta (IL-1 beta) induces transforming growth factor-beta, (TGF-beta 1) production by rat aortic smooth muscle cells. Biochem Biophys Res Commun 1994;204:1186-1192.
23. Mangar SA, Foo K, Norman A, et al. Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clin Oncol (R Coll Radiol) 2006;18:466-473.
24. Hays DM, Raney RB, Wharam MD, et al. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant chemotherapy, with or without radiotherapy. A report from the intergroup rhabdomyosarcoma study (IRS) committee. J Pediatr Hematol Oncol 1995;17:46-52.
25. Yeung CK, Ward HC, Ransley PG, et al. Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer 1994;70:1000-1003.
26. Ozkan KU, Bauer SB, Khoshbin S, et al. Neurogenic bladder dysfunction after sacrococcygeal teratoma resection. J Urol 2006; 175:292 - 296.
27. Mosiello G, Gatti C, De Gennaro M, et al. Neurovesical dysfunction in children after treating pelvic neoplasms. BJU Int 2003;92:289-292.
28. Cruccetti A, Kiely EM, Spitz L, et al. Pelvic neuroblastoma: Low mortality and high morbidity. J Pediatr Surg 2000;35:724-728.
29. Raney B, Anderson J, Jenney M, et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: A report the International workshop. J Urol 2006;176:2190-2194.
30. Blaivas JG. The neurophysiology of micturition: A clinical study of 550 patients. J Urol 1982;127:958-963.
31. Hoover M, Bowman LC, Crawford SE, et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol 1999; 32:353-359.
32. Decter RM, Bauer SB. Urologic management of spinal cord injury in children. Urol Clin N Am 1993;20:475-483.
33. Barrieras D, Lapointe S, Reddy PP, et al. Urinary retention after bilateral extravesical ureteral reimplantation: Does dissection distal to the ureteral orifice have a role? J Urol 1999; 162:1197-1200.
34. Pieters RS, Niemierko A, Fullerton BC, et al. Cauda equina tolerance to high-dose fractionated irradiation. Int J Radiat Oncol Biol Phys 2006;64:251-257.
35. Hoenig DM, McRae S, Chen SC, et al. Transitional cell carcinoma of the bladder in the pediatric patient. J Urol 1996;156:203-205.
36. Agarwala S, Hemal AK, Seth A, et al. Transitional cell carcinoma of the urinary bladder following exposure to cyclophosphamide in childhood. Eur J Pediatr Surg 2001;11:207-210.
37. Kersun LS, Wimmer RS, Hoot AC, et al. Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer 2004;42:289-291.
38. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in 5-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-629.
39. Travis LB, Curtis RE, Glimelius B, etal. Bladderandkidneycancer following cyclophosphamide therapy for non-Hodgkin's lym-phoma. J Natl Cancer Inst 1995;87:524-530.
40. Parekh DJ, Jung C, O'Conner J, et al. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology 2002;60:164.
41. Pedersen-Bjergaard J, Jonsson V, Pedersen M, et al. Leiomyosar- coma of the urinary bladder after cyclophosphamide. J Clin Oncol 1995;13:532-533.
42. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2006;24:476-483.
43. DeLair SM, White RW, Kurzrock EA. Secondary transitional cell carcinoma and nitrogen mustard treatment. Urology 2005;65: 1226-1227.
44. Reznikoff CA, Belair CD, Yeager TR, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996;23:571-584.
45. Khan MA, Travis LB, Lynch CF, et al. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998;7:397-403.
46. Winn RJ, Botnick WZ. The NCCN guideline program: A conceptual framework. Oncology 1997;11:25-32.
47. Bloom DA, Seeley WW, Ritchey ML, et al. Toilet habits and continence in children: An opportunity sampling in search of normal parameters. J Urol 1993;149:1087-1090.
48. Farhat W, Bagli DJ, Capolicchio G, et al. The dysfunctional voiding scoring system: Quantitative standardization of dysfunctional voiding symptoms in children. J Urol 2000;164:1011-1015.
49. Ippoliti C, Przepiorka D, Mehra R, et al. Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology 1995;46:811-815.
50. Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology 2005;65:649-653.
51. Liu YK, Harty JI, Steinbock GS, et al. Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen. J Urol 1990;144:41-43.
52. Hampson SJ, Woodhouse CR. Sodium pentosanpolysulphate in the management of haemorrhagic cystitis: Experience with 14 patients. Eur Urol 1994;25:40-42.
53. Geisler JP, LinnemeierGC,Manahan KJ. Recombinant factor VIIa to treat late radiation-induced hemorrhagic cystitis. J Reprod Med 2008;53:350-352.
54. Ashrani AA, Gabriel DA, Gajewski JL, et al. Pilot study to test the efficacy and safety of activated recombinant factor VII (Novos-even) in the treatment of refractory hemorrhagic cystitis following high dose chemotherapy. Bone Marrow Transplant 2006;38:825-828.
55. Donahue LA, Frank IN. Intravesical formalin for hemorrhagic cystitis: Analysis of therapy. J Urol 1989;141:809-812.
56. Koc S, Hagglund H, Ireton RC, et al. Successful treatment of severe hemorrhagic cystitis with cystectomy following matched donor allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2000;26:899-901.
57. Harris CF, Cooper CS, Hutcheson JC, et al. Appendicovesicos- tomy: The mitrofanoff procedure-a 15-year perspective. J Urol 2000;163:1922-1926.
58. Metcalfe PD, Casale AJ, Kaefer MA, et al. Spontaneous bladder perforations: A report of 500 augmentations in children and analysis of risk. J Urol 2006;175:1466-1470.
59. Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004;172:1649-1651; discussion 1651-1642.